Objectives: Therapy for relapsing-remitting multiple sclerosis with natalizumab (Tysabri; Biogen Idec) has been shown to be effective in the reduction of the clinical relapse rate and disability progression. However, real-life longitudinal data, including years before baseline, are rare.
I n the pivotal trial of natalizumab therapy for relapsingremitting multiple sclerosis (RRMS; AFFIRM), 1 the clinical relapse rate was reduced by 68% compared with placebo in the first year of treatment. Furthermore, the probability of disability progression was decreased. 2 Several subsequent studies have confirmed the efficacy of natalizumab. 3Y10 However, real-life longitudinal data, including years before baseline and especially on patients with a high score in the Expanded Disability Status Scale (EDSS) at baseline, are rare. The present study provides such real-life data on 64 natalizumab-treated MS patients with a mean (SD) baseline EDSS score of 4.5 (1.7).
PATIENTS AND METHODS
We conducted our study in compliance with the principles of the Declaration of Helsinki.
An observational single-center study was carried out. Inclusion criteria were natalizumab treatment of RRMS according to the modified McDonald criteria 11 and availability of standardized clinical data, collected in our MS center, on at least 1 year before and 1 year after initiation of natalizumab treatment. Relapses were defined according to McDonald criteria. PASW statistics version 18 was used for analysis of variance statistics (IBM, New York, NY). When data were only available for a subset of patients, for example, the 2-and 3-year follow-up data, we compared the available data with those patients' baseline data only and excluded baseline data of the other patients. Data were exploratively stratified by baseline EDSS, baseline ARR, median disease duration, and prior therapies.
RESULTS
Sixty-four consecutive patients were enrolled. Two additional patients developed persisting anti-natalizumab antibodies, 1 developed an allergic reaction, and 1 developed a progressive multifocal leukoencephalopathy. These 4 patients were not included into further analyses. At baseline, mean (SD) age was 41 (10) years (range, 22Y68 years). Forty-seven patients (73%) were female, and 17 (27%) were male. Disease duration was 9.9 (7.5) years (range, 0Y29 years). Sixteen patients (25%) had no prior immunomodulating or immunosuppressive therapy other than steroids, 33 (52%) had been treated with A-interferons only, 2 (3%) with glatiramer acetate only, 6 (9%) with both Ainterferons and glatiramer acetate one after another, and 7 (11%) had immunosuppressant treatment after A-interferon and/or glatiramer acetate treatment. Two patients had had an additional treatment with immunoglobulins.
Initiation of natalizumab treatment reduced the ARR in the entire population as well as in subgroups defined by a moderate or high ARR at baseline, respectively ( Table 1 and Fig. 1A ). The ARR was significantly reduced during the 3 years observed. In addition, natalizumab treatment also reduced the EDSS score in the first year ( Table 1 ). The EDSS score after 2 and 3 years was still lower in comparison to the baseline EDSS score of the respective patients, but this was not significant, consistent with the smaller effect size and the smaller sample group. The EDSS score reduction was similar when stratified by limitation versus nonlimitation of walking distance (Fig. 1B) . Reduction of ARR and EDSS score was also independent of age, sex, or disease duration (not shown). Concerning patients without previous treatment, ARR baseline versus first year was 2.52 (0.87) versus 0.38 (0.74) (=85% reduction, P G 0.001). For patients receiving therapy with interferons or glatiramer acetate before the time of natalizumab initiation, ARR baseline versus first year was 1.95 (1.0) versus 0.29 (0.46) (=85% reduction, P G 0.001). In the first year of natalizumab treatment, the EDSS score improved in 22 (34%) of 64 patients and was stable in further 31 (48%) of 64 patients. After 2 years, the EDSS score was better than baseline in 12 (32%) and equal in 18 (49%) of 37 patients, and after 3 years, the EDSS score was better in 6 (26%) and equal in 13 (57%) of 23 patients. Clinical freedom of disease activity, that is, no relapses and improved or stable EDSS, was observed in 43 (73%) of 59, 13 (35%) of 37, and 8 (35%) of 23 patients after 1, 2, and 3 years of natalizumab treatment. Regarding the years before baseline, ARR in the first year of treatment was significantly lower in comparison to 1 (P = 0.012) and 2 (P = 0.001) years before baseline and also ARR of the second and third year after initiation was lower compared with 1 (P = 0.017 and P = 0.010) and 2 years (P = 0.042 and P = 0.022) before treatment initiation ( Table 1 and Fig. 1A ). This was not significant for the EDSS score (Table 1) .
DISCUSSION
Natalizumab has been shown to be effective in the treatment of RRMS. 1Y9 However, longitudinal real-life data are rare.
The Swedish national postmarketing surveillance study demonstrated sustained efficacy of natalizumab treatment for the Swedish population. 10 For the present population, similar results were obtained with data collected in our MS center standardized to the McDonald criteria. 11 Natalizumab treatment is often initiated after a period of active disease resulting in a high baseline ARR. It cannot be excluded that, in the natural course of disease, the ARR of the next year would have been lower again, even without initiation of natalizumab therapy. Thus, comparison of follow-up data during natalizumab therapy should be performed not only with baseline but also with the disease activity before baseline. In our study, the ARR in the first 3 years was significantly lower not only in comparison to baseline data but also to 1 and 2 years before baseline, demonstrating a sustained efficacy not derived from a bias concerning the evaluation of baseline data. Moreover, ARR reduction in the first year was identical in patients without treatment and patients under treatment with interferons or glatiramer acetate at treatment initiation. These data confirm the efficacy of natalizumab in patients with active disease, regardless if treatment naive/currently untreated or under first-line immunomodulating therapy. In our group of patients, the efficacy of natalizumab during 3 years according to the reduction on ARR and, in part, EDSS, was confirmed. The effect of natalizumab on patients with a more advanced disease severity, that is, with a reduced walking distance, was comparable to patients without reduced walking distance, showing a remarkable stabilization and slight improvement on EDSS score indicating the positive effect of natalizumab on EDSS score compared to the natural course of the disease. 12 
CONCLUSIONS
Our study reinforces that natalizumab is efficient in the treatment of RRMS independent of baseline ARR, baseline EDSS score, or baseline treatment. Improvement after baseline is not likely to be biased by exceptionally high disease activity at the time point of natalizumab initiation as shown by the data from year(s) before baseline. Efficacy of natalizumab therapy persists over years. The benefits of natalizumab treatment must be weighed against the risks.
